top of page

Metformin at the Start of COVID and the Risk of Long COVID: Two Trials, Two Strengths of Result

Writer: Joyce Knieff, NMD, LAc
Joyce Knieff, NMD, LAc
Nov 3
5 min read

Most people who catch COVID now recover within a week or two [4]. For a smaller group, symptoms like fatigue, brain fog, or a racing heart on standing last for months. That lingering illness is what researchers call long COVID. In a new commentary in Clinical Infectious Diseases, two researchers argue that a cheap, familiar diabetes drug taken in the first days of infection can lower the chance of developing it [1].


Smiling woman relaxing at home with a cup of tea
Image by StockSnap via Pixabay

What the metformin trials found


The commentary was written by Dr. Carolyn Bramante and Dr. David Boulware of the University of Minnesota, who led the main trials they discuss [1]. It is an opinion piece that reviews four sources: two randomized trials and two analyses of health records. Since a commentary is one step removed from the data, I went to the two trials themselves.


The first, COVID-OUT, enrolled adults aged 30 to 85 with overweight or obesity who had tested positive within the previous three days [2]. Participants took metformin or a placebo, and neither the participants nor the researchers knew who got which. Over the following 10 months, 6.3 percent of the metformin group received a long COVID diagnosis from a medical provider, compared with 10.4 percent of the placebo group. That is a 41 percent lower relative risk, or about 4 fewer cases for every 100 people treated. In the smaller subgroup who started metformin within three days of symptoms, the relative risk was 63 percent lower, although that estimate was less precise [2]. Long COVID was a secondary outcome in this trial, which means it was planned in advance but was not the main question the trial was built to answer.


The second trial, ACTIV-6, tested the same idea in 2,983 lower-risk adults, most of whom had already been vaccinated or infected before [3]. Its main outcome was the share of people who still had symptoms they put down to COVID six months later. Only 2.6 percent did, and the difference between metformin and placebo did not reach the threshold for success that the researchers set before the trial started. The secondary outcome, a long COVID diagnosis from a clinician, was about half as common with metformin, but the absolute difference was less than one person in 100 [3].


What other metformin research has found


The ACTIV-6 researchers also measured the acute illness itself. People on metformin did not recover from their COVID symptoms any faster than people on placebo, with a median of 9 days versus 10 [4]. Seven people on metformin and three on placebo had a serious adverse event over six months, and low blood sugar was rare in both groups [4].


Treatment for people who already have long COVID is a separate question. A 2024 living systematic review in the BMJ combined the results of 24 randomized trials on long COVID treatment [5]. A living review is one the authors keep updating as new trials are published. The reviewers found moderate-certainty evidence that an online cognitive behavioral therapy program and a supervised program combining physical and mental health rehabilitation probably help, and that intermittent aerobic exercise probably improves physical function more than continuous exercise. For many of the other treatments tested, including coenzyme Q10 and a probiotic-prebiotic combination, they found no compelling evidence of benefit [5].


Checking how the body handles standing after COVID


A lot of my patients with long COVID describe symptoms that involve the autonomic nervous system. That is the part of the nervous system that controls heart rate and blood pressure without you having to think about it. In a UK study of 277 patients from eight long COVID clinics, researchers had each person do a standardized standing test called the NASA Lean Test [6]. Over half developed symptoms such as dizziness or palpitations during the test, and 15 percent had an abnormal result, including 7 percent who met criteria for postural orthostatic tachycardia syndrome (POTS). Nearly half of those with an abnormal test had never reported typical symptoms beforehand [6].


Because of that finding, I include a standing test when I assess anyone who has not recovered after an infection, along with questions about things like sleep, digestion, and stress load. What I see clinically is that it is not uncommon for people with post-viral fatigue to have more than one system involved, and sorting out which ones are affected gives us a better place to start than any single remedy.


Should you ask about metformin when you test positive?


Metformin is a prescription medication. The clinician who writes your prescriptions is the person who can decide if it is a good fit for you, and I can't recommend it for any individual in a blog post.


  1. Timing. The strongest result in COVID-OUT came when metformin was started within three days of symptoms [2]. If you have risk factors and want to explore this, call your prescriber early rather than waiting to see how the week goes.

  2. Who was studied. COVID-OUT enrolled adults with overweight or obesity, and ACTIV-6 enrolled mostly lower-risk, previously immune adults [2, 3]. The results apply most directly to people like those participants.

  3. A lean test if symptoms linger. If symptoms like dizziness, exhaustion, or shortness of breath are still there weeks after an infection, ask your provider about an in-office standing or lean test [6].

  4. Pacing and rehabilitation for long COVID. Structured rehabilitation and intermittent rather than continuous exercise have the best support so far [5], and it helps to do them with a clinician or therapist who can adjust the plan as you respond.


References


  1. Bramante CT, Boulware DR. Preventing Long COVID With Metformin. Clin Infect Dis. 2026;82(3):e433-e435. PMID 41608911. doi:10.1093/cid/ciaf700. Original article (AANP digest): https://pmc.ncbi.nlm.nih.gov/articles/PMC13017490/

  2. Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119-1129. PMID 37302406. doi:10.1016/S1473-3099(23)00299-2

  3. Bramante CT, Stewart TG, Boulware DR, et al. Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial. Clin Infect Dis. 2026. PMID 42240559. doi:10.1093/cid/ciag335

  4. Bramante CT, Stewart TG, Boulware DR, et al. Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA Intern Med. 2025;185(9):1092-1101. PMID 40658388. doi:10.1001/jamainternmed.2025.2570

  5. Zeraatkar D, Ling M, Kirsh S, et al. Interventions for the management of long covid (post-covid condition): living systematic review. BMJ. 2024;387:e081318. PMID 39603702. doi:10.1136/bmj-2024-081318

  6. Lee C, Greenwood DC, Master H, et al. Prevalence of orthostatic intolerance in long covid clinic patients and healthy volunteers: A multicenter study. J Med Virol. 2024;96(3):e29486. PMID 38456315. doi:10.1002/jmv.29486


This post is for education only and is not medical advice. Metformin is a prescription medication with its own risks and interactions. Please talk with your own prescriber before starting, stopping, or changing any medication, and with your healthcare provider about any lingering symptoms after an infection.



If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.




 
 
 

Comments


bottom of page